MarketCapExport financials
ANI Pharmaceuticals (ANIP)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
ANI Pharmaceuticals Balance Sheet 2025-2008 | ANIP
Brief overview of ANI Pharmaceuticals's assets and capital
The balance sheet is assessed across five available annual reports spanning 2021 to 2025.
The asset base grew from $771.6 million to $1.4 billion, or +86.7%. Average annual growth of roughly 16.9% was strong.
Liabilities grew faster than assets: +117.9% versus +86.7%. A substantial part of expansion was externally funded.
Shareholders' equity accounts for 37.5% of assets, previously 43.3%. Dependence on liabilities is moderate.
Net debt to equity stands at 0.02x; the current burden does not look excessive.
Cash accounts for 19.8% of assets versus 13% initially. The change indicates the degree of financial flexibility.
Retained earnings remain negative at -$23.1 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Overall assessment
The balance sheet gives no single signal for ANI Pharmaceuticals: some indicators are sound, while leverage or capitalization needs attention.
Annual Balance Sheet ANI Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
8.18 M | 166 M | 65.3 M | 238 M | 187 M | 178 M | 123 M | 140 M | 170 M | 93.3 M | -41.3 M | -58.3 M | -11.1 M | -26.9 M | -39.9 M | - | - | - |
Long Term Debt |
292 M | 309 M | 285 M | 286 M | 287 M | 172 M | 176 M | 67.3 M | 198 M | 121 M | 113 M | 111 M | - | - | 17.3 M | - | - | - |
Long Term Debt Current |
1.92 M | 1.8 M | 1.56 M | 684 K | 850 K | 13.2 M | 9.94 M | 3.26 M | 3.35 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 182 M | 67.8 M | 198 M | 121 M | 113 M | 111 M | - | - | 17.3 M | - | - | - |
Total Current Liabilities |
278 M | 194 M | 145 M | 99.4 M | 87.5 M | 78.6 M | 61.7 M | 166 M | 39.2 M | 31.9 M | 11.8 M | 13.2 M | 3.54 M | 10.6 M | 7.23 M | 8.18 M | - | - |
Total Liabilities |
900 M | 856 M | 447 M | 422 M | 413 M | 265 M | 244 M | 233 M | 237 M | 153 M | 125 M | 124 M | 3.54 M | 10.6 M | 24.6 M | 25.6 M | - | - |
Deferred Revenue |
- | - | - | - | - | 80 K | 451 K | 711 K | - | - | - | - | 47 K | - | - | - | - | - |
Retained Earnings |
-23.1 M | -100 M | -80.1 M | -97.3 M | -47.8 M | -4.97 M | 17.6 M | 11.5 M | -4.01 M | -2.92 M | -4.35 M | -19.7 M | -48.5 M | -245 M | -217 M | -166 M | - | - |
Total Assets |
1.44 B | 1.28 B | 904 M | 760 M | 772 M | 461 M | 457 M | 431 M | 412 M | 323 M | 285 M | 264 M | 44.5 M | 38.8 M | 62.4 M | 44.8 M | - | - |
Cash and Cash Equivalents |
286 M | 145 M | 221 M | 48.2 M | 100 M | 7.86 M | 62.3 M | 43 M | 31.1 M | 27.4 M | 155 M | 169 M | 11.1 M | 11 K | 57.2 M | 38.2 M | 29.9 M | 11.8 M |
Book Value |
541 M | 429 M | 458 M | 339 M | 359 M | 196 M | 213 M | 197 M | 175 M | 170 M | 160 M | 140 M | 41 M | 28.2 M | 37.8 M | 19.1 M | - | - |
Total Shareholders Equity |
541 M | 404 M | 433 M | 314 M | 334 M | 196 M | 213 M | 197 M | 175 M | 170 M | 160 M | 140 M | 41 M | -42.7 M | 37.8 M | 19.1 M | 15.8 M | 13.8 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet ANI Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
280 M | 286 M | 298 M | 301 M | 305 M | 313 M | 284 M | - | 285 M | 285 M | 285 M | 286 M | 286 M | 286 M | 286 M | 287 M | 186 M | 190 M | 169 M | 172 M | 172 M | 172 M | 172 M | 176 M | 176 M | 176 M | 176 M | 67.3 M | 67.3 M | 67.3 M | 67.3 M | 69.9 M | 69.9 M | 69.9 M | 69.9 M | - | 121 M | 121 M | 121 M | 113 M | 113 M | 113 M | 113 M | 107 M | 111 M | 111 M | 111 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
897 M | 860 M | 902 M | 881 M | 849 M | 857 M | 440 M | - | 435 M | 425 M | 426 M | 422 M | 402 M | 414 M | 399 M | 413 M | 279 M | 288 M | 260 M | 265 M | 265 M | 265 M | 265 M | 244 M | 244 M | 244 M | 244 M | 233 M | 233 M | 233 M | 233 M | 237 M | 237 M | 237 M | 237 M | 153 M | 153 M | 153 M | 153 M | 125 M | 125 M | 125 M | 125 M | 120 M | 124 M | 124 M | 124 M | 3.54 M | - | - | 9.33 M | 10.6 M | 10.9 M | 16.4 M | 16.6 M | 24.6 M | 24.6 M | 24.6 M | 24.6 M |
Deferred Revenue |
- | - | - | - | - | 5 M | - | - | - | - | - | - | - | - | 116 K | 87 K | 62 K | 62 K | 62 K | 80 K | 80 K | 80 K | 318 K | 451 K | 451 K | 558 K | 624 K | 711 K | 735 K | 711 K | 711 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
31.1 M | 6.39 M | -50.6 M | -76.9 M | -85 M | -89.6 M | -65 M | - | -80.9 M | -90.4 M | -96.3 M | -97.3 M | -92.6 M | -83.6 M | -68.3 M | -47.8 M | -23.4 M | -19 M | -4.89 M | -4.97 M | -4.97 M | -4.97 M | -4.97 M | 17.6 M | 17.6 M | 17.6 M | 17.6 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | -4.01 M | -4.01 M | -4.01 M | -4.01 M | -2.92 M | -2.92 M | -2.92 M | -2.92 M | -4.35 M | -4.35 M | -4.35 M | -4.35 M | -19.7 M | -19.7 M | -19.7 M | -19.7 M | -48.5 M | -48.5 M | -48.5 M | -48.5 M | -43.8 M | -43.8 M | -43.8 M | -245 M | -217 M | -217 M | -217 M | -217 M |
Total Assets |
1.49 B | 1.42 B | 1.41 B | 1.34 B | 1.29 B | 1.29 B | 921 M | - | 890 M | 859 M | 765 M | 760 M | 739 M | 751 M | 745 M | 772 M | 470 M | 480 M | 464 M | 461 M | 461 M | 461 M | 461 M | 457 M | 457 M | 457 M | 457 M | 431 M | 431 M | 431 M | 431 M | 412 M | 412 M | 412 M | 412 M | 323 M | 323 M | 323 M | 323 M | 285 M | 285 M | 285 M | 285 M | 260 M | 264 M | 264 M | 264 M | 44.5 M | 44.5 M | 44.5 M | 44.5 M | 13.7 M | 13.7 M | 13.7 M | 38.8 M | 62.4 M | 62.4 M | 62.4 M | 62.4 M |
Cash and Cash Equivalents |
360 M | 311 M | 263 M | 218 M | 150 M | 145 M | 240 M | 229 M | 193 M | 162 M | 67.8 M | 48.2 M | 56.3 M | 63.4 M | 76.9 M | 100 M | 15.3 M | 24.3 M | 25.1 M | 7.86 M | 7.86 M | 7.86 M | 7.86 M | 62.3 M | 62.3 M | 62.3 M | 62.3 M | 43 M | 43 M | 43 M | 43 M | 31.1 M | 31.1 M | 31.1 M | 31.1 M | 27.4 M | 27.4 M | 27.4 M | 27.4 M | 155 M | 155 M | 155 M | 155 M | 169 M | 169 M | 169 M | 169 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 11 K | 11 K | 11 K | 34.8 M | - | 57.2 M | 57.2 M | 57.2 M |
Book Value |
597 M | 562 M | 506 M | 462 M | 443 M | 431 M | 481 M | - | 455 M | 434 M | 339 M | 339 M | 337 M | 337 M | 346 M | 359 M | 191 M | 192 M | 204 M | 196 M | 196 M | 196 M | 196 M | 213 M | 213 M | 213 M | 213 M | 197 M | 197 M | 197 M | 197 M | 175 M | 175 M | 175 M | 175 M | 170 M | 170 M | 170 M | 170 M | 160 M | 160 M | 160 M | 160 M | 140 M | 140 M | 140 M | 140 M | 41 M | 44.5 M | 44.5 M | 35.2 M | 3.15 M | 2.83 M | -2.63 M | 22.2 M | 37.8 M | 37.8 M | 37.8 M | 37.8 M |
Total Shareholders Equity |
597 M | 562 M | 506 M | 437 M | 419 M | 406 M | 456 M | - | 430 M | 410 M | 315 M | 314 M | 312 M | 312 M | 321 M | 334 M | 191 M | 192 M | 204 M | 196 M | 196 M | 196 M | 196 M | 213 M | 213 M | 213 M | 213 M | 197 M | 197 M | 197 M | 197 M | 175 M | 175 M | 175 M | 175 M | 170 M | 170 M | 170 M | 170 M | 160 M | 160 M | 160 M | 160 M | 140 M | 140 M | 140 M | 140 M | 41 M | 41 M | 41 M | 41 M | -42.7 M | -42.7 M | -42.7 M | 28.2 M | -34.3 M | 37.8 M | 37.8 M | 37.8 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of ANI Pharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Russia
USA
Canada
Niderland
France
Israel
Australia
Danmark
Irlanda
